Compare · NPCE vs SYK
NPCE vs SYK
Side-by-side comparison of Neuropace Inc. (NPCE) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NPCE and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $93.70B, about 464.3x NPCE ($201.8M).
- SYK has been more active in the news (5 items in the past 4 weeks vs 3 for NPCE).
- SYK has more recent analyst coverage (25 ratings vs 15 for NPCE).
- Company
- Neuropace Inc.
- Stryker Corporation
- Price
- $16.84-0.09%
- $327.50-0.63%
- Market cap
- $201.8M
- $93.70B
- 1M return
- +25.26%
- -
- 1Y return
- +44.94%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 15
- 25
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NPCE
- SEC Form DEFA14A filed by Neuropace Inc.
- SEC Form DEF 14A filed by Neuropace Inc.
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Morrell Martha
- SEC Form 4 filed by Geiger Uri
- SEC Form 4 filed by Lacob Joseph
- SEC Form 4 filed by Kumar Rakhi
- SEC Form 4 filed by Fischer Frank M
- NeuroPace to Present at the Leerink Global Healthcare Conference
- CHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew